{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:47Z","timestamp":1792093787849,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Camurus in collaboration with Novartis Pharma AG."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00280-018-3734-1","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T06:48:19Z","timestamp":1544251699000},"page":"375-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study"],"prefix":"10.1007","volume":"83","author":[{"given":"Marianne","family":"Pavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cailleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libuse","family":"Tauchmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Tiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,8]]},"reference":[{"issue":"1","key":"3734_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.seminoncol.2012.11.003","volume":"40","author":"M Pavel","year":"2013","unstructured":"Pavel M, Kidd M, Modlin I (2013) Systemic therapeutic options for carcinoid. Semin Oncol 40(1):84\u201399. \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.003","journal-title":"Semin Oncol"},{"issue":"11","key":"3734_CR2","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. \n                    https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3734_CR3","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1185\/03007990903328959","volume":"25","author":"L Anthony","year":"2009","unstructured":"Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25(12):2989\u20132999. \n                    https:\/\/doi.org\/10.1185\/03007990903328959","journal-title":"Curr Med Res Opin"},{"issue":"28","key":"3734_CR4","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R, Group PS (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4656\u20134663. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"3734_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D, National comprehensive cancer n (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13 (1):78\u2013108","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3734_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, Investigators C (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371(3):224\u2013233. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1316158","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"3734_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","volume":"286","author":"HA Schmid","year":"2008","unstructured":"Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286(1\u20132):69\u201374. \n                    https:\/\/doi.org\/10.1016\/j.mce.2007.09.006","journal-title":"Mol Cell Endocrinol"},{"key":"3734_CR8","unstructured":"Sandostatin\u00ae LAR Depot Dosing & Administration|HCP (2017) Novartis Pharmaceuticals Corporation, East Hanover. \n                    https:\/\/www.hcp.novartis.com\/products\/sandostatin-lar-depot\/carcinoid-syndrome\/dosing-administration\/#mixing-and-administration-guide\n                    \n                  . Accessed 27 Jun 2017"},{"issue":"1","key":"3734_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1773-2247(11)50009-7","volume":"21","author":"F Tiberg","year":"2011","unstructured":"Tiberg F, Johnsson M (2011) Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles. J Drug Deliv Sci Technol 21(1):101\u2013109","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"3734_CR10","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1246\/cl.2012.1090","volume":"41","author":"F Tiberg","year":"2012","unstructured":"Tiberg F, Johnsson M, Jankunec M, Barauskas J (2012) Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions. Chem Lett 41(10):1090\u20131092. \n                    https:\/\/doi.org\/10.1246\/cl.2012.1090","journal-title":"Chem Lett"},{"issue":"3","key":"3734_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bcp.12698","volume":"80","author":"F Tiberg","year":"2015","unstructured":"Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, Linden M (2015) Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol 80(3):460\u2013472. \n                    https:\/\/doi.org\/10.1111\/bcp.12698","journal-title":"Br J Clin Pharmacol"},{"key":"3734_CR12","volume-title":"WHO classification of tumours of the digestive system","author":"FTCF Bosman","year":"2010","unstructured":"Bosman FTCF, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system, vol\u00a03, 4th edn. International Agency for Research on Cancer (IARC), Lyon","edition":"4"},{"key":"3734_CR13","unstructured":"Sandostatin\u00ae LAR Depot (octreotide acetate for injectable suspension) [prescribing information] (2016) Novartis Pharmaceuticals Corporation, East Hanover. \n                    https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/sandostatin_lar.pdf\n                    \n                  . Accessed 27 Jun 2017"},{"issue":"5","key":"3734_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-11-0367","volume":"19","author":"LK Kvols","year":"2012","unstructured":"Kvols LK, Oberg KE, O\u2019Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B (2012) Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 19(5):657\u2013666. \n                    https:\/\/doi.org\/10.1530\/ERC-11-0367","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"3734_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00280-013-2202-1","volume":"72","author":"EM Wolin","year":"2013","unstructured":"Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol 72(2):387\u2013395. \n                    https:\/\/doi.org\/10.1007\/s00280-013-2202-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3734_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40262-015-0329-4","volume":"55","author":"N Buil-Bruna","year":"2016","unstructured":"Buil-Bruna N, Garrido MJ, Dehez M, Manon A, Nguyen TX, Gomez-Panzani EL, Troconiz IF (2016) Population pharmacokinetic analysis of lanreotide autogel\/depot in the treatment of neuroendocrine tumors: pooled analysis of four clinical trials. Clin Pharmacokinet 55(4):461\u2013473. \n                    https:\/\/doi.org\/10.1007\/s40262-015-0329-4","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3734_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1517\/17425255.2010.513700","volume":"6","author":"M Hu","year":"2010","unstructured":"Hu M, Tomlinson B (2010) Pharmacokinetic evaluation of lanreotide. Expert Opin Drug Metab Toxicol 6(10):1301\u20131312. \n                    https:\/\/doi.org\/10.1517\/17425255.2010.513700","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"13","key":"3734_CR18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.2165\/11204510-000000000-00000","volume":"70","author":"LP Yang","year":"2010","unstructured":"Yang LP, Keating GM (2010) Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70(13):1745\u20131769. \n                    https:\/\/doi.org\/10.2165\/11204510-000000000-00000","journal-title":"Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3734-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T00:19:29Z","timestamp":1575764369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3734-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,8]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MP received honoraria for presentations or advisory board from Novartis, IPSEN, Pfizer, and Lexicon. AC has nothing to disclose. FBC received consulting fees for advisory board from Novartis, Ipsen, Merck Serono, Bayer, and Pfizer; honorarium for speaking from Bayer, HAC, and Genzyme. DH received personal fees from Lexicon Pharma, grants and personal fees from Ipsen Pharma Inc, during the conduct of the study; personal fees from Lexicon Pharma Inc; grants and personal fees from Ipsen Pharma Inc, Novartis Pharma Inc, and Pfizer Pharma Inc, outside the submitted work. HL received consulting fees from Novartis. RP received research grant as principal investigator and co-investigator, and lecturer fee and honoraria from Novartis; research grant as clinical researcher, consulting fees, and honoraria as speaker from Shire; research grant as principal investigator from Ipsen and Pfizer. LT and CD are employees of Novartis. HO and FT are employees of Camurus. DF received consulting fee for lectures or advisory boards, and research funding for preclinical research project from Novartis; received consulting fee for advisory boards, and research funding for preclinical research project from Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and applicable local regulations. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. All patients provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}